Initial Experience of Pancreaticoduodenectomy in a Newly Developed Hepato-pancreato-Biliary Unit Serving in a Lower-Middle Income Country
Abstract
Introduction: Pancreaticoduodenectomy (PD) is the only potentially curative treatment for pancreatic head adenocarcinoma. This study aimed to determine short-term outcomes of PD performed over one year at a newly established Hepato-Pancreatico-Biliary (HPB) unit in Khyber Pakhtun Khwa (KPK) Province of Pakistan. Material and methods: A retrospective analysis of a prospectively maintained Hospital Information System (HIS) was undertaken of all patients referred to the unit between May 2021 to August 2022. Data were collected from the medical records of patients in the hospital information system. Data were analyzed for primary location, age, complications, and operative parameters. Results: The primary site of disease were ampulla (n=18, 52.9%), pancreas (n=11, 32.4%), and duodenum (n=5, 14.7%). The median duration of surgery was 7 hours. 16 (47.1%) patients required blood transfusion either intraoperatively or in the peri-operative period. Patients with preoperative biliary drainage (PBD) were more likely to have multidrug-resistant positive bile cultures with a p-value of 0.2 [n=12(35.3%) vs n=5(14.7%)]. Overall morbidity was 38.2%. The most common complications were wound infection (n=12, 35.3%), delayed gastric emptying (n=6, 17.6%), and type B pancreatic fistula (n=3, 8.8%). The complication rate was higher in patients with biliary stenting [n=11(32.4%) vs n=2 (5.9%); p-value 0.06]. The median length of hospital stay for patients without complications was less (6 vs 12 days; P<.001). The complication rate was lower in Total Laparoscopic PD (TLPD) with p=0.4 (TLPD;2.9%, open; 23.5%, laparoscopic-assisted;11.8%). 90-day mortality was zero. Conclusion: Short-term outcomes for PD in our facility are comparable to high-volume centers. Preoperative biliary drainage can significantly increase operative time, hospital stay, and morbidity.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.
Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.